Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / IMAB - Week In Review: Suzhou's Adagen Raises $140 Million In U.S. IPO To Develop Oncology Drugs

IMAB - Week In Review: Suzhou's Adagen Raises $140 Million In U.S. IPO To Develop Oncology Drugs

I-MAB
  • Adagene completed a $140 million NASDAQ IPO and climbed 56% higher in open market trading.
  • Nuance Pharma in-licensed Greater China rights to a late-stage candidate for osteoarthritis pain from Antibe Therapeutics in a $100 million agreement.
  • Junshi Biosciences and Eli Lilly announced their dual mAb treatment was approved in the US to treat COVID-19 under emergency use rules.

For further details see:

Week In Review: Suzhou's Adagen Raises $140 Million In U.S. IPO To Develop Oncology Drugs
Stock Information
Company Name: I-MAB
Stock Symbol: IMAB
Market: NASDAQ
Website: i-mabbiopharma.com
Menu
IMAB IMAB Quote IMAB Short IMAB News IMAB Articles IMAB Message Board
Get IMAB Alerts

News, Short Squeeze, Breakout and More Instantly...